Alcon Shareholders Reject Novartis Offer As Inadequate

When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52% stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23%, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders.